AMLX vs MDGL vs JPM vs IQV vs BAC

For growth investors, Madrigal Pharmaceuticals, Inc.

(MDGL) is the stronger pick with 432. 1% revenue growth year-over-year, versus -100. 0% for Amylyx Pharmaceuticals, Inc. (AMLX). Bank of America Corporation (BAC) offers the better valuation at 14. 7x trailing P/E (12. 6x forward), making it the more compelling value choice. Analysts rate Amylyx Pharmaceuticals, Inc. (AMLX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bank of America Corporation (BAC) is the cheapest at 14.

7x versus IQVIA Holdings Inc. at 23. 1x. On forward P/E, Bank of America Corporation is actually cheaper at 12. 6x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IQVIA Holdings Inc. wins at 0. 35x versus Bank of America Corporation's 0. 82x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Madrigal Pharmaceuticals, Inc.

(MDGL) delivered a total return of +346. 6%, compared to -25. 8% for IQVIA Holdings Inc. (IQV). Over 10 years, the gap is even starker: MDGL returned +39. 4% versus AMLX's -13. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Madrigal Pharmaceuticals, Inc.

(MDGL) is the lower-risk stock at 0. 49β versus Amylyx Pharmaceuticals, Inc. 's 1. 40β — meaning AMLX is approximately 183% more volatile than MDGL relative to the S&P 500. On balance sheet safety, Amylyx Pharmaceuticals, Inc. (AMLX) carries a lower debt/equity ratio of 2% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Madrigal Pharmaceuticals, Inc.

(MDGL) is pulling ahead at 432. 1% versus -100. 0% for Amylyx Pharmaceuticals, Inc. (AMLX). On earnings-per-share growth, the picture is similar: Amylyx Pharmaceuticals, Inc. grew EPS 65. 5% year-over-year, compared to 1. 5% for JPMorgan Chase & Co.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -30. 1% for Madrigal Pharmaceuticals, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -31. 3% for MDGL. At the gross margin level — before operating expenses — MDGL leads at 94. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, IQVIA Holdings Inc. (IQV) is the more undervalued stock at a PEG of 0. 35x versus Bank of America Corporation's 0. 82x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Bank of America Corporation (BAC) trades at 12. 6x forward P/E versus 14. 4x for JPMorgan Chase & Co. — 1. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AMLX: 88. 5% to $27. 50.

In this comparison, BAC (2.

3% yield), JPM (1. 9% yield) pay a dividend. AMLX, MDGL, IQV do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Bank of America Corporation (BAC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

86), 2. 3% yield, +368. 2% 10Y return). Both have compounded well over 10 years (BAC: +368. 2%, AMLX: -13. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (AMLX (Healthcare) and MDGL (Healthcare) and JPM (Financial Services) and IQV (Healthcare) and BAC (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: AMLX is a small-cap quality compounder stock; MDGL is a mid-cap high-growth stock; JPM is a large-cap deep-value stock; IQV is a mid-cap quality compounder stock; BAC is a large-cap deep-value stock. JPM, BAC pay a dividend while AMLX, MDGL, IQV do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.